Dr. Kanter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UNM Hospital Emergency Medicine
2211 Lomas BLVD NE
Albuquerque, NM 87131Phone+1 505-272-6225Fax+1 786-662-5251
Education & Training
- University of New Mexico School of MedicineResidency, Emergency Medicine, 2006 - 2009
- Case Western Reserve University School of MedicineClass of 2006
Certifications & Licensure
- FL State Medical License 2009 - 2027
- NM State Medical License 2006 - 2012
- American Board of Emergency Medicine Emergency Medicine
Clinical Trials
- Dose-Finding Study of SC411 in Children With Sickle Cell Disease Start of enrollment: 2017 Mar 02
- Evaluating Barriers to Stroke Screening and Prevention in Children With Sickle Cell Disease Start of enrollment: 2018 Feb 12
Publications & Presentations
Abstracts/Posters
- Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi PanelJulie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene TherapyJulie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene TherapyJulie Kanter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Advancing Science in Sickle Cell Disease: Implications for the Future of Care61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
- Insurance Requirements for Prior Authorization May Prompt ‘Devastating’ DelaysMarch 10th, 2023
- New Gene Therapies Are a near-Cure for Louisiana's Sickle Cell Patients. But at $1-2M, Who Will Pay for It?March 5th, 2023
- Specialized Centers Can Help Realign the U.S.’s Moral Compass for Sickle Cell DiseaseDecember 21st, 2022
- Join now to see all
Grant Support
- Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell diseaseUNIVERSITY OF ALABAMA AT BIRMINGHAM2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: